ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.000
+0.080 (2.74%)
Jul 31, 2026, 4:08 PM HKT

HKG:1541 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-218.58-315.86-379.46-402.89-732.95
Depreciation & Amortization
14.6120.6822.5817.6213.18
Loss (Gain) From Sale of Assets
-----0.56
Asset Writedown & Restructuring Costs
-27.4---
Loss (Gain) From Sale of Investments
-0.06-14.15-1.76--1.6
Stock-Based Compensation
15.7734.2171.64103.8334.02
Other Operating Activities
5.38-5.45-5.2420.69521.45
Change in Accounts Receivable
0.020.020.03-0.030.01
Change in Accounts Payable
-19.6327.576.364.887.65
Change in Unearned Revenue
-7.6532.9---
Change in Other Net Operating Assets
7.5664.64-81.7117.21-31.74
Operating Cash Flow
-202.58-128.04-367.55-238.71-190.54
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1.31-10.4-2.69-23.22-40.7
Sale of Property, Plant & Equipment
----0.58
Investment in Securities
-61.8840.72-303.37-23.65
Other Investing Activities
72.927.6311.2123.27-92.25
Investing Cash Flow
9.7337.95-294.850.05-108.72

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
----0.01
Long-Term Debt Issued
251.96175.7879.96--
Total Debt Issued
251.96175.7879.96-0.01
Short-Term Debt Repaid
-----0.01
Long-Term Debt Repaid
-159.78-125.8-26.21-5.8-4.77
Total Debt Repaid
-159.78-125.8-26.21-5.8-4.78
Net Debt Issued (Repaid)
92.1849.9853.76-5.8-4.77
Issuance of Common Stock
320.35215.94307.79189.57800.98
Other Financing Activities
-10.18-6.99-30.51-4.39-3.17
Financing Cash Flow
402.36258.93331.04179.38793.03

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-7.541.793.1426.17-9.12
Miscellaneous Cash Flow Adjustments
--0.01---
Net Cash Flow
201.96170.62-328.23-33.11484.65

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-203.9-138.44-370.25-261.93-231.24
Free Cash Flow Growth
-----
Free Cash Flow Margin
-132.15%-186.70%-4811.50%-4603.41%-1674.69%
Free Cash Flow Per Share
-0.49-0.37-1.02-0.79-2.68
Levered Free Cash Flow
-65.6-135.44-193.42-2,538-
Unlevered Free Cash Flow
-62.28-133.29-192.47-2,537-

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
5.33.451.520.790.89
Change in Working Capital
-19.7125.13-75.3222.05-24.08